Great f.y.i. Get hooked here!
SOMERSET, N.J. — (BUSINESS WIRE) — Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that its wholly owned subsidiary, Catalent
Q2’21 net revenue of $910.8 million increased 26% as-reported, or 24% in constant currency, compared to Q2’20. Organic, constant currency net revenue grew 17%, compared to Q2’20. Q2’21 net earnings of $88.4 million increased 94%, or 88% in constant currency, compared to
Q1’21 net revenue of $845.7 million increased 27% as-reported, or 26% in constant currency, compared to Q1’20. On an organic basis, constant currency net revenue in Q1’21 grew 20% compared to Q1’20. Q1’21 Adjusted EBITDA of $174.4 million increased 37% as-reported, or